Sanofi (SNY)

Executive Summary

Sanofi is a French multinational biopharmaceutical company that ranks among the top 10 globally by revenue, with a diversified portfolio spanning immunology, oncology, rare diseases, vaccines, and diabetes care. The company leverages deep immunoscience expertise and artificial intelligence across its R&D value chain to accelerate drug discovery and development. With 34 commercial products—including blockbusters like Dupixent (co-developed with Regeneron), Lantus, and various vaccines—Sanofi has a strong revenue base. However, the company faces upcoming patent expirations on key assets and is pivoting toward innovative therapies in immunology and rare diseases. Recent strategic moves include spinning off its consumer health business and advancing a late-stage pipeline focused on next-generation immunology drugs (e.g., amlitelimab for atopic dermatitis, tolebrutinib for multiple sclerosis) and vaccines (e.g., a recombinant COVID-19 booster). Despite near-term headwinds, Sanofi's R&D productivity and diversified business model provide resilience. The conviction score reflects a balanced risk-reward profile given the company's incumbent position and pipeline potential.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 data readout for tolebrutinib in relapsing multiple sclerosis65% success
• H1 2027FDA decision on amlitelimab (SAR441566) for moderate-to-severe atopic dermatitis60% success
• Q2 2027Completion of consumer health business spin-off90% success